🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
271 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"
2025-524434-25-00gastric cancer
Centre Hospitalier Universitaire De Bordeaux
Neoplasms
France
30/04/2026
Phase II
Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE
2025-524511-36-00Neurology
Hospices Civils De Lyon
Nervous System Diseases
France
30/04/2026
Phase II
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
2025-521154-42-00Sickle Cell Disease
CSL Behring LLC
Hemic and Lymphatic Diseases
Belgium, Netherlands, France, Italy
28/04/2026
Phase II
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)
2025-521967-11-00The study population includes adult ICU patients with a hos…
Assistance Publique Hopitaux De Paris
Mental Disorders
France
28/04/2026
Phase II
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase II
Methylphenidate for Early Awakening in Coma (MEAWAKE)
2025-524937-19-00Coma due to acute brain injury
Rigshospitalet
Nervous System Diseases
Austria, Denmark, Germany, France
27/04/2026
Phase II
Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM
2025-524602-15-00Neurology
Hospices Civils De Lyon
Nervous System Diseases
France
24/04/2026
Phase II
A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease
2025-520641-69-00Kidney disease
Medizinische Universitaet Innsbruck
Immune System Diseases
Germany, Austria, France
23/04/2026
Phase II
NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial
2025-523683-20-00Postmenopausal patients with small (pT1a-b pN0) hormone rec…
Unicancer
Neoplasms
France
21/04/2026
Phase II
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase II
IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease
2025-522790-10-00Non Small Cell Lung Cancer, Interstitial Lung Disease
Intergroupe Francophone De Cancerologie Thoracique
Neoplasms
France
17/04/2026
Phase II
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
MaaT PHARMA
Digestive System Diseases
Netherlands, Italy, France, Spain
17/04/2026
Phase II
METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0
2025-522655-26-00METAREM:Patients with advanced cancer, as defined as unrese…
Unicancer
Neoplasms
France
16/04/2026
Phase II
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)
Dompe' Farmaceutici S.p.A.
Nervous System Diseases
Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland
14/04/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer
2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer
Genmab A/S
Neoplasms
Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland
14/04/2026
Phase II
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2025-522965-31-00Atopic Dermatitis
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany, Bulgaria, France
14/04/2026
Phase II
A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)
2025-523117-28-00Relapsed or Refractory Multiple Myeloma
Glaxosmithkline Research & Development Limited
Neoplasms
France, Germany, Greece, Netherlands, Spain
13/04/2026
Phase II
A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)
2025-520976-25-00Relapsed/refractory multiple myeloma
Centre Hospitalier Universitaire De Saint Etienne
Hemic and Lymphatic Diseases
France
09/04/2026
Phase II
Retinoic acid and sperm production in infertile men
2024-519644-33-00oligozoospermia
Les Hopitaux Universitaires De Strasbourg
Not possible to specify
France
09/04/2026
Phase II
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
2025-522867-13-00Non Small Cell Lung Cancer
Merus B.V.
Not possible to specify
Spain, Belgium, Netherlands, Poland, Italy, France
09/04/2026
Phase II
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myel…
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
08/04/2026
Phase II
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
2025-522288-13-00Patients with pretreated extensive-stage small cell lung ca…
ETOP IBCSG Partners Foundation
Neoplasms
France, Greece, Spain, Italy
08/04/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy
2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy
Rycarma Therapeutics Inc.
Musculoskeletal Diseases
Netherlands, Spain, France, Germany
02/04/2026
Phase II
A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa
2025-521865-29-00moderate-to-severe hidradenitis suppurativa
Almirall S.A.
Skin and Connective Tissue Diseases
Bulgaria, Spain, France, Poland, Germany
01/04/2026
Phase II
PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
2024-511510-20-00craniopharyngioma
Prinses Maxima Centrum voor Kinderoncologie B.V.
Neoplasms
Netherlands, France, Germany
25/03/2026
Rows per page Showing 101–125 of 271
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.